Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method

This study aims to determine whether low-dose oral VDRA increases serum FGF23 level and whether the combination of VDRA and LC inhibits this increase. The results will be useful in the management of CKD –mineral and bone disorder in predialysis patients.Trial registrationUMIN000030503. Registered 20 January 2018.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research